Table 4 Univariate analysis of PFS and OS according to treatment, AR status and Grade Group 2–4 versus 5.

From: Grade group system and plasma androgen receptor status in the first line treatment for metastatic castration resistant prostate cancer

 

PFS

OS

n. pts

n. events

Median PFS (months) (95% CI)

p

HR (95% CI)

p

n. events

Median OS (months) (95% CI)

p

HR (95% CI)

p

ABI/ENZA

94

58

16.2 (10.1–18.9)

–

–

–

40

27.4 (21.0–43.8)

–

–

–

AR Normal

Grade group 2–4

61

36

17.1 (11.9–22.3)

 

1.00

 

22

36.7 (24.5–nr)

 

1.00

 

Grade group 5

18

10

16.6 (8.6–51.5)

0.83

0.93 (0.44–1.93)

0.84

7

44.2 (18.3–52.8)

0.94

1.03 (0.44–2.43)

0.94

AR gain

Grade group 2–4

8

7

6.6 (1.6–35.8)

 

1.00

 

5

20.2 (4.0–35.8)

 

1.00

 

Grade group 5

7

5

6.6 (2.8–13.7)

0.75

1.21 (0.36–4.04)

0.75

5

7.8 (6.0–13.7)

0.02

4.92 (0.92–26.27)

0.04

Docetaxel

70

70

9.9 (8.9–11.0)

–

–

–

59

35.4 (28.7–44.5)

–

–

–

AR normal

Grade group 2–4

32

32

10.6 (8.4–11.4)

 

1.00

 

25

40.4 (28.7–57.8)

 

1.00

 

Grade group 5

15

15

8.5 (5.8–10.8)

0.28

1.41 (0.75–2.65)

0.28

14

29.8 (14.9–49.2)

0.11

1.71 (0.87–3.36)

0.11

AR gain

Grade group 2–4

15

15

9.8 (3.5–12.7)

 

1.00

 

13

31.9 (20.0–44.5)

 

1.00

 

Grade group 5

8

8

10.1 (6.5–30.3)

0.34

0.63 (0.24–1.66)

0.35

7

33.0 (17.3–107.0)

0.32

0.60 (0.21–1.68)

0.32

  1. AR androgen receptor, ABI abiraterone, ENZA enzalutamide, PFS progression free survival, OS overal survival, nr not reached, ne not estimable, HR hazard ratio, n number, nr not reached, ne not estimable.
Back to article page